Alaunos Therapeutics, Inc.

As of November 14, 2023, Alaunos Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to significant negative financial ratios, including a Price to Book Value of 4.70 and a ROCE of -416.30%, despite a recent stock price surge.

As of June 11, 2025, the trend is mildly bullish due to positive weekly MACD and KST indicators, but mixed signals from the RSI, Bollinger Bands, and Dow Theory suggest caution in the bullish outlook.

As of March 2022, the management team of Alaunos Therapeutics, Inc. includes Chairman James Huang, CEO Dr. Laurence Cooper, Lead Independent Director Heidi Hagen, and Directors J. Kevin Buchi, Jaime Vieser, Holger Weis, and Independent Director Dr. Christopher Bowden. They oversee the company's strategic direction and operations.

Alaunos Therapeutics, Inc. is a micro-cap biopharmaceutical company focused on developing cancer therapies in the immuno-oncology sector. As of March 2025, it reported net sales of $0 million and a net loss of $1 million, with a market cap of $6 million.

As of Jun 18, Alaunos Therapeutics, Inc. has a market capitalization of 6.00 million, with net sales of 0.00 million and a net profit of -4.07 million over the latest four quarters. The company reported shareholder's funds of 2.06 million and total assets of 2.75 million as of Dec 24.